Systemic Radiation Therapy Group

  • Visiting addressShow on map

    Universitetssjukhuset

    22184 Lund

    Sweden

Unit profile

Research

The main research area of the group is systemic treatment of metastasized cancer using therapeutic radionuclides. To optimize dose delivery to tumor cells, radionuclides are conjugated to tracer molecules, e.g. antibodies or antibody fragments, targeting cancer-specific epitopes. Preclinical evaluation of treatment combinations and strategies aim to improve treatment efficacy. Multimodality imaging such as SPECT/PET/CT, and Cerenkov and Bioluminescence Imaging are also employed to evaluate tracer biokinetics, biological effects and properties such as tumor uptake and penetration. Improving micro- and macro-scale dosimetry models and apply them using input from e.g. imaging modalities is another key aim. The group combines basic research with translational efforts, aiming to implement novel radionuclide therapies in the clinic. The current focus is on prostate cancer radioimmunotherapy targeting human kallikrein-related peptidase 2 (hK2), following promising preclinical results.

UKÄ subject classification

  • Cancer and Oncology
  • Radiology, Nuclear Medicine and Medical Imaging

Free keywords

  • Nuclear Medicine
  • Medical Imaging
  • Molecular Imaging
  • Radioimmunotherapy
  • Radiation Therapy
  • Dosimetry
  • Prostate Cancer
  • hk2

UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. Our work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or